2003 Press Releases Communiqués de presse

December 16, 2003 16 December, 2003

Pheromone Sciences Corp. Announces that Rights Offering Does Not Hit Minimum Levels

November 10, 2003 10 November, 2003

Pheromone Sciences Corp Announces Rights Offering

August 11, 2003 11 August, 2003

Pheromone Successfully Completes Dairy Cow Fertility Monitoring Study

August 5, 2003 5 August, 2003

Pheromone Sciences Signs Chinese Distribution Agreement

June 23, 2003 23 June, 2003

Pheromone Sciences Issued U.S. Patent on Pheromone's Sensing and Reporting Technology

February 25, 2003 25 February, 2003

Pheromone Sciences Enters Advanced Dairy Testing

January 14, 2003 14 January, 2003

Pheromone Sciences Appoints Jim Wooder to Board of Directors

January 7, 2003 7 January, 2003

Pheromone Sciences Corp. Completes Private Placement Offering

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 16, 2003 16 December, 2003

Pheromone Sciences Corp. Announces that Rights Offering Does Not Hit Minimum Levels


Toronto, Ontario - December 16, 2003 - Pheromone Sciences Corp. (TSX-V: PHS) today announced that its Shareholder Rights Offering, which expired on December 12, 2003, has not raised the minimum gross proceeds of $285,000.

Accordingly, the Company will not be accepting subscriptions to acquire common shares pursuant to the exercise of rights and will return any subscription funds received to subscribers without interest. The company is scaling down its operations to conserve available cash while it aggressively pursues other financing options with a view to sustain the Company to pursue promising options to achieve licensing and commercialization of its Fertility Monitor product.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT Lorne Woods (800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 10, 2003 10 November, 2003

Pheromone Sciences Corp Announces Rights Offering


Toronto -- November 10, 2003 -- Pheromone Sciences Corp. (TSX Venture: PHS) -- Pheromone Sciences Corp. ("Pheromone" or the "Company") today announced that it will be conducting a Rights Offering in which it will issue to holders of its outstanding common shares as of November 20, 2003 one Right for each common share held. Every four Rights will entitle shareholders resident in British Columbia, Alberta, Manitoba and Ontario (the "Qualifying Jurisdictions") to subscribe for one common share of Pheromone at a subscription price of $0.11 at anytime on or prior to December 12, 2003. Rights of shareholders resident outside the Qualifying Jurisdictions will be held by CIBC Mellon Trust Company who will attempt to sell such Rights at such prices and otherwise in such manner as it may determine in its sole discretion. The Rights will be listed and posted for trading on the TSX Venture Exchange. Minimum gross proceeds of $285,000 are required to be raised through this Rights Offering to continue the Company as a going concern beyond December 31, 2003.

"The company needs working capital while we are in discussions with several potential commercialization partners for our PSC Fertility Monitor(�) . We remain enthused with our current technology and the company's prospects as described in the offering circular", said Christopher Neuman, President and CEO, Pheromone Sciences.

In recognition of the financial position of the Company and in consideration of the Chief Executive Officer and the Chief Financial Officer waiving any entitlement to severance or termination pay on termination of employment or to accrued vacation pay, and as an inducement to both officers, the Company has granted to these individuals, subject to regulatory approval, the right to earn a bonus payable in common shares of the Company. The Chief Executive Officer can earn 1,000,000 shares and the Chief Financial Officer can earn 600,000 shares if one of several milestones are achieved by March 1, 2004, including, the Company entering into a licensing agreement or other commercialization agreement for its PSC Fertility Monitor(tm), or a financing for gross proceeds of a minimum of $1 million or a sale or merger of the Company.

For further information with respect to the Rights Offering please contact Christopher Neuman, President and Chief Executive Officer or Larry Cooper, Chief Financial Officer at 416-861-9854.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 11, 2003 11 August, 2003

Pheromone Successfully Completes Dairy Cow Fertility Monitoring Study


Toronto, Ontario (August 11, 2003) -- Pheromone Sciences Corp (TSX: PHS), today announced that it has successfully completed its first field trial of its proprietary fertility and ovulation detection technology for large animal breeding at the Ontario Veterinary College under the direction of Dr. Walter H. Johnson DVM, MVSc, Dipl. ACT, and Professor of Theriogenology at the University of Guelph.

The trial, which used devices designed for human wear comprised enrolling 55 cows as registered subjects with a view to evaluating the sensors ability to detect hormone- related changes indicative of heat. Adequate sensor data as well as complete progesterone and ultrasound records were obtained in 32 of these subjects that reflected a 58% operational trial enrollment completion success rate.

The trial's endpoint results coupled with the simulation derived from proposed changes to the computer algorithm suggest that the Company's ability to adapt its proprietary Fertilit�©-OVâ�¢ Monitor technology to the specific physiology of the dairy cow in the dairy farm environment, can meet a success level, defined as the correct prediction of oncoming estrus, of 60%. Additional feasibility trials will be undertaken to further study and confirm this anticipated success rate upon implementation of the changes to the computer algorithm. The actual "window of opportunity" for dairy cow breeding would be predictions of ovulation - -2 days to 0 days before ovulation, a recognized requirement for successful breeding.

"These results compare very favorably to those rates achieved with current technologies available to the small and large scale dairy farmer," commented Dr. Johnson. "We are very pleased that this collaboration with the scientific staff of Pheromone Sciences, continues to build momentum. "A product that can increase conception rates in dairy herd breeding would positively impact productivity on dairy farms across North America", Dr. Johnson added.

Dairy industry researchers estimate that within the North American dairy industry U.S. producers incur revenue losses directly attributable to inefficient herd reproduction management of approx. US$400 million per annum. The ability to provide accurate monitoring of the fertility status of commercial livestock would afford a significant commercial opportunity for both the agricultural community and Pheromone Sciences Corp.

"We are enthusiastic about the results from this trial at the Ontario Veterinary College. We were pleased to be able to identify parameters which will help adapt the technology to the farm environment," said Doug Marett, Pheromone Sciences Chief Scientific Officer. "We will now look to optimize the design as part of the process of bringing this product to the commercialization stage in the future.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 05, 2003 5 August, 2003

Pheromone Sciences Signs Chinese Distribution Agreement


Toronto, Ontario (August 5, 2003) - Pheromone Sciences Corp. (TSX Venture: PHS), a Toronto based biotech company and the developer of the Fertilit�©- OVâ�¢ monitoring device with proprietary technology in the field of non-invasive fertility and ovulation detection is pleased to announce that it has entered into a long-term definitive distribution and licensing agreement with Ningxia St Edenweiss.

Under the agreement, Ningxia St Edenweiss, a public company whose shares are traded on China's Shenzhen Stock Exchange (symbol 000982) has obtained marketing and distribution rights for Pheromone's Fertilit�©-OV monitor in China, Hong Kong, Macao and Taiwan. Ningxia St Edenweiss is a manufacturing and marketing company with well-established relationships throughout the Chinese medical community. Pheromone shall receive upfront, milestone and royalty payments typical of a transaction of this nature.

Ningxia St. Edenweiss will immediately institute the filing process for Chinese regulatory approval with product approval expected to be complete within 12 months time.

"This relationship with Pheromone Sciences is a clear demonstration of Ningxia St. Edenweiss's ability and capacity to market new and innovative technologies," stated Ningxia St. Edenweiss Chairman Mr. Hou Yuqian. "We look forward to introducing the Fertilit�©- OV monitor as well as other new medical devices into this growing marketplace."

"The completion of this agreement represents a significant milestone for Pheromone Sciences while contributing to the health care needs of couples seeking help in conception", stated Christopher Neuman, President and CEO of Pheromone. "We are confident that the Fertilit�©- OV monitor will have an equally positive response in other markets throughout the world.

The Fertilit�©-OV monitor is a fertility cycle monitoring device for the consumer and professional medical market and provides a reliable "predictive" approach to natural, cycle-based family planning. The Fertilit�©- OV monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio-sensing and computer technologies These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

A US based party, previously reported in the notes to the company's financial statements as having provided a non- refundable standby fee has determined that the product is not a suitable strategic fit with their current business model at this time. Efforts remain ongoing with other out-licensing prospects both in the US and other jurisdictions.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 23, 2003 23 June, 2003

Pheromone Sciences Issued U.S. Patent on Pheromone's Sensing and Reporting Technology


Toronto, Ontario (July 23, 2003) -- Pheromone Sciences Corp (TSX-V: PHS), a developer of fertility prediction medical devices for both human and large animal applications, today announced that the U.S. Patent Office has issued patent No. 6,592,529 covering Pheromone's sensing and reporting technology in the early prediction of ovulation for female mammals, including humans, using innovative measurements of sweat ion concentrations. Fertility prediction and detection is of daily interest to the lives of millions of women across the United States.

"This patent will serve as a valuable asset as we work through licensing opportunities with potential strategic partners in both the human and large animal marketplaces", remarked Christopher Neuman, President and CEO of Pheromone Sciences. "The patent recognizes the propriety position of Pheromone's unique technology for ovulation detection through the non invasive measurement of sweat ion constituents and demonstrates our ongoing commitment to the development of a comprehensive intellectual property portfolio."

The patent is also applicable to the Company's veterinary program. Within the North American dairy industry, it is estimated that about 2 million dairy cows are monitored for their ovulation date at any given point in time as a precursor to artificial insemination procedures being provided to these cattle.

About Pheromone Sciences Corp:

PHEROMONE SCIENCES is a biotechnology and medical diagnostics & device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

PHEROMONE SCIENCES has capitalized on its potentially breakthrough sensing and reporting technology initially through the development of two products:

- Fertilit�©-OVâ�¢ monitor, a non- invasive fertility cycle monitoring device for the medical professional & consumer market which provides up to 4 days advance notice of ovulation and thereby improving the probability and speed of conception. The product is approved for marketing in the USA, Canada and Western Europe and the company is currently in discussions for marketing and sales partnerships to bring this technology to the consumer.

- The company is currently in feasibility studies that may in the future bring this technology to the dairy industry.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 25, 2003 25 February, 2003

Pheromone Sciences Enters Advanced Dairy Testing


Toronto, Ontario (February 25, 2003) -- Pheromone Sciences Corp (TSX-V:PHS), is pleased to announce the commencement of advanced testing of its proprietary sensing technology for large animal breeding at the Ontario Veterinary College, University of Guelph, under the direction of Dr. Walter Johnson. This testing is designed to generate core data required to fully adapt the Company's PSC Fertility Monitor for use in detecting hormone and ovulation patterns in dairy cows. This work is scheduled to be completed at the end of Q3.

As part of this effort, the company is pleased to announce the engagement of Dr. Linda Rhodes VMD, PhD as consultant to help design and manage the best possible clinical program for the animal breeding technology. Within this ongoing program, the Company looks to generate efficacy and economic data for use by the target market. Dr Rhodes' experience combines over 23 years in dairy cattle veterinary practice, research in reproductive physiology, and human and animal drug discovery and development. Dr. Rhodes has experience with designing and executing clinical trials and leading product development teams in the veterinary pharmaceutical industry.

"We are very excited about this next stage of the development process for our PSC Fertility Monitor technology and continue tracking toward completion of this agricultural program next year." said Christopher Neuman, President and CEO of Pheromone Sciences.

This novel program is based on the same core technology employed within the FDA approved PSC Fertility Monitor for human use. Successful completion of the agricultural program next year would create a non-invasive, safe and easy to use fertility and ovulation detection device for use in cattle breeding operations. Currently, some US$400 million is lost each year in North America due to timing issues in breeding dairy herds.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 14, 2003 14 January, 2003

Pheromone Sciences Appoints Jim Wooder to Board of Directors


Toronto, Ontario (January 14, 2003) - Pheromone Sciences Corp (TSX-V:PHS), is pleased to announce the appointment of Mr. Jim Wooder, well-known and respected Toronto businessman, to its Board of Directors.

Mr. Wooder brings a wealth of investment knowledge and business acumen to the Pheromone Sciences' Board of Directors. He is currently Vice President of Helix Investments (Canada) Inc., a North American- based venture capital company with assets of $200 million. Mr. Wooder has held this position since 1993. Prior to this Mr.Wooder spent several years in the Canadian Banking Industry. In addition, Mr. Wooder has held senior management positions with prominent investment and venture capital firms.

Having participated at the Board of Director level in some 50 companies, Mr Wooder is Chairman of The Hanen Centre, an internationally renowned charity that develops programs to assist teachers and parents in the teaching of children with speech problems.

"We are extremely pleased that Mr. Wooder has accepted this appointment to our Board. His experience and proven abilities as a manager and investor will be of benefit to us as we enter this crucial phase in our development and growth ", commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp.

The appointment, which is subject to regulatory approval, is part of an ongoing program to enhance the independent nature of the Board.

In addition, Mr. Douglas Marett's duties as Chief Scientific Officer are now being carried out on a consulting basis.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 07, 2003 7 January, 2003

Pheromone Sciences Corp. Completes Private Placement Offering


Toronto, Ontario - January 7, 2003 - Pheromone Sciences Corp. (TSX-V:PHS) today announced that it has completed a private placement; of 2,140,000 units of the Company at an issue price of $0.25 per unit for gross proceeds of $535,000. Each unit will be exercisable, at no additional consideration, into one common share of the Company and one common share purchase warrant. Each common share purchase warrant has a term of 12 months and will be exercisable into one common share at an exercise price of $0.30 per share.

Subscribers included a senior Ontario based biotech institution, company insiders and 2 private investors.

Proceeds of the offering will be used to support the Company's research and development program, ongoing operations, and business development.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods (800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com